Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies
Authors:
Open Access
- 18 January 2017
- journal article
- review article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (13) , 22218-22234
Abstract
Triple negative breast cancer (TNBC) is still an incurable disease despite the great scientific effort performed during the last years. The huge heterogeneity of this disease has motivated the evaluation of a great number of therapies against different molecular alterations. In this article, we review the biological bases of this entity and how the known molecular evidence supports the current preclinical and clinical development of new therapies. Special attention will be given to ongoing clinical studies and potential options for future drug combinations.Keywords
This publication has 105 references indexed in Scilit:
- TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast CancerPLOS ONE, 2013
- The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genesGenes & Development, 2011
- Higher population‐based incidence rates of triple‐negative breast cancer among young African‐American womenCancer, 2011
- Susceptibility Pathways in Fanconi's Anemia and Breast CancerNew England Journal of Medicine, 2010
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene, 2010
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitorThe EMBO Journal, 2008
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast CancerJNCI: Journal of the National Cancer Institute, 2003